Aussie court tosses Lipitor suit against Pfizer; Novartis nabs FDA approval for multiple myeloma med;

> Pfizer's ($PFE) strategy of offering steep Lipitor rebates as the drug's patent neared expiration didn't constitute anticompetitive conduct, an Australian judge said, tossing a lawsuit filed by the Australian Competition and Consumer Commission. Report (sub. req.)

> Novartis ($NVS) won FDA approval for its multiple myeloma drug Farydak, as a third line treatment. Report

> The global cancer drug market is expected to hit $111 billion by 2020, new market research shows. Report

> Hospira ($HSP) and Celltrion launched their biosimilar versions of Remicade in Europe, where the brand earned €2 billion last year. Report (reg. req.)

And Finally... Preventive treatment with an HIV drug reduced infection by 86% in gay men at high risk of contracting the disease. Report

Suggested Articles

Cardiac risks associated with roxadustat are comparable to placebo in nondialysis patients and to Amgen's standard, Epogen, in those on dialysis.

Pfizer and Merck KGaA's immuno-oncology agent Bavencio failed another gastric cancer study, this time as a maintenance treatment after chemotherapy.

A jury ordered Biogen to pay nearly $6 million to a former sales manager who reported a colleague's misconduct and got fired a few months later.